“Latest Stem Cells News”

In the decades-long war on cancer, as of late, researchers had been making little progress in comparison to colleagues treating other conditions, such as cardiac or infectious diseases. “Cancer research has really plateaued out,” William Matsui, an associate professor of oncology at Johns Hopkins University‘s School of Medicine, said at the 2009 World Stem Cell Summit here on Tuesday. But pushing cancer stem cell research “gives us a novel way to study cancer,” said Matsui, who also runs a lab at the university’s Sidney Kimmel Comprehensive Cancer Center.

Cancer and stem cells have had a fraught relationship—not in the least because of early concern that stem cell treatments could in fact spur on cancer through their encouragement of undifferentiated cell growth. But cancer stem cells themselves have gained a more solid toe-hold in the past several years as a potential new target for cancer research.

Cancer stem cells—or CSCs—are presumed to have similar capabilities as healthy stem cells: they can regenerate and differentiate into any cell that makes up the cancer. Such cells are often blamed for relapses in patients who by all other measures appear to have been cured. One of the large problems, however, has been in finding these cells. In some cancers, such as some leukemias, they are suspected to be only one cell in a million.

Cancer stem cells’ persistence has given rise to the so-called dandelion theory of cancer treatment. Researchers and doctors have traditionally worked to obliterate the visible cancerous menace—the tumor, or dandelion weed, as it were. But as anyone with a lawn may be well aware, hacking off the flower does little to stop the root—that is, the stem cell—from regenerating another attack later. So, posits Richard Jones, also at the Sidney Kimmel Comparative Cancer Center, it’s possible that effective drugs may have been abandoned because they were not creating quick, visible responses. Eliminating the root stem cells will cause the tumors to stop growing, but not right away, he explained at the summit.

JAMA

Adult Stem Cell Research Shows that Diabetes Type 1 Can Be Helped

In a Stem Cell research study that is being published today in the Journal of American Medical Association (JAMA), Adult Stem Cells have been used to help patients with Diabetes Type 1.

20 of 23 Patients Helped With Their Own Adult Stem Cells

23 patients who were newly diagnosed (within 6 weeks) with Diabetes Type 1 were first given chemotherapy to dampen their immune system, then they were given their own stem cells taken from their blood.

Of those 23 patients, 20 “reduced or ended dependence on insulin as their bodies took over production of the hormone.” Of those 20 patients, 12 of them were off insulin for a long period of time, while 8 relapsed and went back to taking small doses of insulin.

According to the stem cell abstract:

Conclusion After a mean follow-up of 29.8 months following autologous nonmyeloablative HSCT in patients with newly diagnosed type 1 DM, C-peptide levels increased significantly and the majority of patients achieved insulin independence with good glycemic control.

New hope in treating Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s Disease, an incurable neurological disease, which is particularly frequent in former soccer players, may come from stem cells. Nicholas Maragakis and his colleagues from the Johns Hopkins University of Medicine in Baltimore in the United States, have successfully conducted an important experiment in mice. In a study published in the online edition of ‘Nature Neuroscience’, the American researchers transplanted precursor cells called astrocytes, which function as support cells for neurons, into the mice with ALS. This allow the mice to survive for much longer.

ALS, pointed out the authors, is caused by the degeneration and death of so-called motor neurons, which are nervous cells that send signals to muscles to move. Recent research has demonstrated that astrocytes, belonging to the family of glial support cells, could be struck by the disease. Based on this concept, Maragakis’ team tried to treat an animal with ALS by transplanting early astrocytes.

The cells managed to survive in the spinal cord and the mice, although they did not heal completely, were able to survive much longer than normal. The beneficial effects, specified the scientists, require the presence of a particular transport protein in the precursor astrocytes: a scavenger protein able to remove excess glutamated neurotransmitters, a substance that is involved in the development of ALS, from motor neurons tied to astrocytes.